Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.44 |
| ▸ | TPH1 | P17752 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrosine SCHEMBL8315968 | 1.00 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL28433898 | 1.00 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL8316690 | 1.00 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL606713 | 1.00 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL25286397 | 0.96 | SLC7A5 (0.60) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL27792454 | 0.94 | SLC7A5 (0.57) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL8904139 | 0.92 | SLC7A5 (0.55) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL28519346 | 0.92 | SLC7A5 (0.55) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL9978769 | 0.90 | SLC7A5 (0.52) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL18297990 | 0.90 | SLC7A5 (0.52) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109609476-A | α-transaminase and mutant and its application in asymmetric syntheses L-glufosinate-ammonium | 浙江工业大学 | 2019-04-12 | — | — | CN | claimed |
| CN-108185315-A | Sausage without nitrite and preparation method thereof | 浙江省农业科学院 | 2018-06-22 | — | — | CN | claimed |
| CN-107162855-A | A kind of nutrient matrix cultivated for flower plants and nursery stock and preparation method thereof | 安徽省百思德农业发展有限公司 | 2017-09-15 | — | — | CN | claimed |
| CN-107141134-A | A kind of Vegetable Soil modifying agent and preparation method thereof | 合肥卓畅农业科技有限公司 | 2017-09-08 | — | — | CN | claimed |
| US-9458220-B2 | Single-chain insulin agonists exhibiting high activity at the insulin receptor | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-10-04 | — | — | US | claimed |
| US-20150148520-A1 | SINGLE-CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | UNIV INDIANA RES & TECH CORP (US) | 2015-05-28 | — | — | US | claimed |
| CN-104271595-A | Proteins toxic to hemipteran insect species | MONSANTO TECHNOLOGY LLC | 2015-01-07 | — | — | CN | claimed |
| US-20130203665-A1 | SINGLE-CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2013-08-08 | — | — | US | claimed |
| EP-2582719-A2 | SINGLE CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | Indiana University Research And Technology Corporation (US) | 2013-04-24 | — | — | EP | claimed |
| CN-103068842-A | Single chain insulin agonists exhibiting high activity at the insulin receptor | UNIV INDIANA RES & TECH CORP | 2013-04-24 | — | — | CN | claimed |
| WO-2011159895-A2 | SINGLE CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2011-12-22 | — | — | WO | claimed |
| EP-1390074-A4 | NOVEL COMPOSITIONS AND USES THEREFOR | UNIV QUEENSLAND (AU) | 2007-03-14 | — | — | EP | claimed |
| EP-1292615-B1 | MODIFIED MORBILLIVIRUS V PROTEINS | WYETH CORP (US) | 2006-10-25 | — | — | EP | claimed |
| US-20040241177-A1 | For producing antigen-primed antigen-presenting cells for eliciting a humoral and cellular immunity against target antigens; intracellular proteolytic degradation of second antigen is increased; immunogens; sustained release | UNIQUEST PTY LTD (AU) | 2004-12-02 | — | — | US | claimed |
| EP-1390074-A1 | NOVEL COMPOSITIONS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2004-02-25 | — | — | EP | claimed |
| US-6664066-B2 | Mutant measles virus V protein; gene expression and engineering | WYETH HOLDINGS CORPORATION | 2003-12-16 | — | — | US | claimed |
| US-20030206925-A1 | MODIFIED MORBILLIVIRUS V PROTEINS | WYETH HOLDINGS CORPORATION | 2003-11-06 | — | — | US | claimed |
| WO-2002083181-A1 | NOVEL COMPOSITIONS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2002-10-24 | — | — | WO | claimed |
| CN-1232504-A | 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of order designated mononegavirales | AMERICAN CYANAMID CO (US) | 1999-10-20 | — | — | CN | claimed |
| CN-117460418-A | Non-dairy creamer composition | 皇家戴维艾格伯茨有限公司 | 2024-01-26 | — | — | CN | disclosed |
| WO-2023121483-A1 | IMMUNOSTIMULATORY COMPOSITIONS | VICTORIA LINK LIMITED (NZ) | 2023-06-29 | — | — | WO | disclosed |
| CN-114685681-A | Application of HrpNECh protein in pharmacy for recognizing and activating multiple types of receptors and/or membrane proteins and signal pathways thereof | 吴伯骥 | 2022-07-01 | — | — | CN | disclosed |
| US-11351268-B2 | FGF21 C-terminal peptide optimization | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210198647-A1 | Enhancers of Neurolysin Activity | TEXAS TECH UNIVERSITY SYSTEM | 2021-07-01 | — | — | US | disclosed |
| US-20200360530-A1 | FGF21 C-TERMINAL PEPTIDE OPTIMIZATION | UNIV INDIANA RES & TECH CORP (US) | 2020-11-19 | — | — | US | disclosed |
| EP-2970511-B1 | INSULIN-INCRETIN CONJUGATES | UNIV INDIANA RES & TECH CORP (US) | 2020-09-30 | — | — | EP | disclosed |
| US-10696726-B2 | Insulin-incretin conjugates | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| CN-110869384-A | Cell factory with improved delivery of iron-sulfur clusters | 毒菌公司 | 2020-03-06 | — | — | CN | disclosed |
| US-20190336581-A1 | IMMUNOSTIMULATORY COMPOSITIONS AND USES THEREFOR | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2019-11-07 | — | — | US | disclosed |
| US-20190142963-A1 | FGF21 C-TERMINAL PEPTIDE OPTIMIZATION | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2019-05-16 | — | — | US | disclosed |
| CN-109689099-A | Composition for preventing or treating IL-8-related diseases | 中外制药株式会社 | 2019-04-26 | — | — | CN | disclosed |
| EP-3442997-A2 | FGF21 C-TERMINAL PEPTIDE OPTIMIZATION | Indiana University Research & Technology Corporation (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20180305705-A1 | CONSTRUCTS FOR GENE EXPRESSION ANALYSIS | GENE STREAM PTY LTD (AU) | 2018-10-25 | — | — | US | disclosed |
| CN-108697906-A | By the cancer prevention and the treatment that inhibit soluble tumor necrosis factor | 高等教育联邦系统-匹兹堡大学 | 2018-10-23 | — | — | CN | disclosed |
| CN-104271595-B | Proteins toxic to hemipteran insect species | 孟山都技术公司 | 2018-09-18 | — | — | CN | disclosed |
| US-20180194827-A1 | INSULIN-INCRETIN CONJUGATES | UNIV INDIANA RES & TECH CORP (US) | 2018-07-12 | — | — | US | disclosed |
| CN-108271372-A | IL-8-BINDING ANTIBODIES AND USES THEREOF | 中外制药株式会社 | 2018-07-10 | — | — | CN | disclosed |
| US-9993542-B2 | Compositions and uses therefor | Admedus Vaccines Pty Ltd. (AU) | 2018-06-12 | — | — | US | disclosed |
| US-9994858-B2 | Constructs for gene expression analysis | GENE STREAM PTY LTD (AU) | 2018-06-12 | — | — | US | disclosed |
| WO-2018018082-A1 | IMMUNOSTIMULATORY COMPOSITIONS AND USES THEREFOR | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2018-02-01 | — | — | WO | disclosed |
| WO-2017210242-A1 | INSULIN-NUCLEAR HORMONE CONJUGATES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-12-07 | — | — | WO | disclosed |
| US-9795658-B2 | Expression system for modulating an immune response | ADMEDUS VACCINES PTY LTD (AU) | 2017-10-24 | — | — | US | disclosed |
| WO-2017180988-A2 | FGF21 C-TERMINAL PEPTIDE OPTIMIZATION | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-10-19 | — | — | WO | disclosed |
| CN-107162855-A | A kind of nutrient matrix cultivated for flower plants and nursery stock and preparation method thereof | 安徽省百思德农业发展有限公司 | 2017-09-15 | — | — | CN | disclosed |
| CN-107141134-A | A kind of Vegetable Soil modifying agent and preparation method thereof | 合肥卓畅农业科技有限公司 | 2017-09-08 | — | — | CN | disclosed |
| US-20170253932-A1 | METHOD FOR DETECTING BCR-ABL INHIBITOR RESISTANCE-RELATED MUTATION AND DATA ACQUISITION METHOD FOR PREDICTING BCR-ABL INHIBITOR RESISTANCE USING THE SAME | TOYO KOHAN CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
| US-20170224808-A1 | THERAPEUTIC COMPOSITIOJNS AND METHODS FOR INDUCING AN IMMUNE RESPONSE TO HERPES SIMPLEX VIRUS TYPE 2 (HSV-2) | ADMEDUS VACCINES PTY LTD (AU) | 2017-08-10 | — | — | US | disclosed |
| EP-3200821-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR INDUCING AN IMMUNE RESPONSE TO HERPES SIMPLEX VIRUS TYPE 2 (HSV-2) | Admedus Vaccines Pty Ltd (AU) | 2017-08-09 | — | — | EP | disclosed |
| US-20170218393-A1 | EXPRESSION SYSTEM FOR MODULATING AN IMMUNE RESPONSE | ADMEDUS VACCINES PTY LTD (AU) | 2017-08-03 | — | — | US | disclosed |
| EP-1390074-B1 | NOVEL COMPOSITIONS AND USES THEREFOR | ADMEDUS VACCINES PTY LTD (AU) | 2017-06-07 | — | — | EP | disclosed |
| US-9593340-B2 | Expression system for modulating an immune response | Admedus Vaccines Pty Ltd. (AU) | 2017-03-14 | — | — | US | disclosed |
| US-9405884-B2 | Methods and systems for the analysis of protein samples | ABBVIE INC. (US) | 2016-08-02 | — | — | US | disclosed |
| WO-2016049705-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR INDUCING AN IMMUNE RESPONSE TO HERPES SIMPLEX VIRUS TYPE 2 (HSV-2) | ADMEDUS VACCINES PTY LTD (AU) | 2016-04-07 | — | — | WO | disclosed |
| US-20160024169-A1 | INSULIN-INCRETIN CONJUGATES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION | 2016-01-28 | — | — | US | disclosed |
| EP-2970511-A1 | INSULIN-INCRETIN CONJUGATES | Indiana University Research and Technology Corporation (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150132325-A1 | NOVEL COMPOSITIONS AND USES THEREFOR | UNIQUEST PTY LTD (AU) | 2015-05-14 | — | — | US | disclosed |
| CN-104271595-A | Proteins toxic to hemipteran insect species | MONSANTO TECHNOLOGY LLC | 2015-01-07 | — | — | CN | disclosed |
| US-8858951-B2 | Compositions for eliciting an immune response | THE UNIVERSITY OF QUEENSLAND (AU) | 2014-10-14 | — | — | US | disclosed |
| WO-2014158900-A1 | INSULIN-INCRETIN CONJUGATES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2014-10-02 | — | — | WO | disclosed |
| EP-2726097-A2 | HERPES VIRUS VACCINE AND METHODS OF USE | The Regents Of The University Of California (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-2689250-A1 | METHODS AND SYSTEMS FOR THE ANALYSIS OF PROTEIN SAMPLES | AbbVie Inc. (US) | 2014-01-29 | — | — | EP | disclosed |
| WO-2013006569-A2 | HERPES VIRUS VACCINE AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-01-10 | — | — | WO | disclosed |
| WO-2012128810-A1 | METHODS AND SYSTEMS FOR THE ANALYSIS OF PROTEIN SAMPLES | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | WO | disclosed |
| US-20120245857-A1 | Methods and Systems for the Analysis of Protein Samples | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120177668-A1 | IMMUNOMODULATING COMPOSITIONS COMPRISING INTERLEUKIN 13 INHIBITORS AND USES THEREFOR | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2012-07-12 | — | — | US | disclosed |
| US-20120040367-A1 | CONSTRUCT SYSTEM AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2012-02-16 | — | — | US | disclosed |
| US-20110287039-A1 | EXPRESSION SYSTEM FOR MODULATING AN IMMUNE RESPONSE | THE UNIVERSITY OF QUEENSLAND (AU) | 2011-11-24 | — | — | US | disclosed |
| WO-2011009173-A1 | CANCER IMMUNOTHERAPY | MATER MEDICAL RESEARCH INSTITUTE (AU) | 2011-01-27 | — | — | WO | disclosed |
| US-20110020374-A1 | EXPRESSION SYSTEM FOR MODULATING AN IMMUNE RESPONSE | THE UNIVERSITY OF QUEENSLAND (AU) | 2011-01-27 | — | — | US | disclosed |
| WO-2011003138-A1 | IMMUNOMODULATING COMPOSITIONS COMPRISING INTERLEUKIN 13 INHIBITORS AND USES THEREFOR | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2011-01-13 | — | — | WO | disclosed |
| US-20100286229-A1 | Modulation of Androgen Receptor for Treatment of Prostate Cancer | PANACELA LABS, INC. | 2010-11-11 | — | — | US | disclosed |
| EP-2215269-A1 | CONSTRUCT SYSTEM AND USES THEREFOR | The University of Queensland (AU) | 2010-08-11 | — | — | EP | disclosed |
| EP-2215231-A1 | EXPRESSION SYSTEM FOR MODULATING AN IMMUNE RESPONSE | The University of Queensland (AU) | 2010-08-11 | — | — | EP | disclosed |
| CN-101646768-A | Attenuated minus-strand RNA viruses | DNAVEC CORP JP | 2010-02-10 | — | — | CN | disclosed |
| CN-100558901-C | The method of selectively producing male or female sterile plants | SYNGENTA LTD (GB) | 2009-11-11 | — | — | CN | disclosed |
| WO-2009049350-A1 | EXPRESSION SYSTEM FOR MODULATING AN IMMUNE RESPONSE | THE UNIVERSITY OF QUEENSLAND (AU) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009049351-A1 | CONSTRUCT SYSTEM AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2009-04-23 | — | — | WO | disclosed |
| US-20080255000-A1 | Method Evolved for Recognition and Testing of Age Related Macular Degeneration (Mert-Armd) | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2008-10-16 | — | — | US | disclosed |
| EP-1373528-B1 | NOVEL EXPRESSION VECTORS | GENE STREAM PTY LTD (AU) | 2008-08-13 | — | — | EP | disclosed |
| EP-1941061-A1 | METHOD EVOLVED FOR RECOGNITION AND TESTING OF AGE RELATED MACULAR DEGENERATION (MERT-ARMD) | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) | 2008-07-09 | — | — | EP | disclosed |
| US-20070298417-A1 | Constructs for gene expression analysis | PROMEGA CORPORATION | 2007-12-27 | — | — | US | disclosed |
| WO-2007056111-A1 | METHOD EVOLVED FOR RECOGNITION AND TESTING OF AGE RELATED MACULAR DEGENERATION (MERT-ARMD) | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-05-18 | — | — | WO | disclosed |
| EP-1390074-A4 | NOVEL COMPOSITIONS AND USES THEREFOR | UNIV QUEENSLAND (AU) | 2007-03-14 | — | — | EP | disclosed |
| US-7157272-B2 | Constructs for gene expression analysis | GENE STREAM PTY LTD. (AU) | 2007-01-02 | — | — | US | disclosed |
| EP-1292615-B1 | MODIFIED MORBILLIVIRUS V PROTEINS | WYETH CORP (US) | 2006-10-25 | — | — | EP | disclosed |
| CN-1639344-A | Method for selectively producing male or female sterile plants | SYNGENTA LTD (GB) | 2005-07-13 | — | — | CN | disclosed |
| EP-1373528-A4 | NOVEL EXPRESSION VECTORS | GENE STREAM PTY LTD (AU) | 2004-12-29 | — | — | EP | disclosed |
| US-20040241177-A1 | For producing antigen-primed antigen-presenting cells for eliciting a humoral and cellular immunity against target antigens; intracellular proteolytic degradation of second antigen is increased; immunogens; sustained release | UNIQUEST PTY LTD (AU) | 2004-12-02 | — | — | US | disclosed |
| US-20040209274-A2 | Constructs for Gene Expression Analysis | GENE STREAM PTY LTD (AU) | 2004-10-21 | — | — | US | disclosed |
| US-20040115704-A1 | Constructs for gene expression analysis | DALY JOHN (AU) | 2004-06-17 | — | — | US | disclosed |
| EP-1390074-A1 | NOVEL COMPOSITIONS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2004-02-25 | — | — | EP | disclosed |
| EP-1373528-A1 | NOVEL EXPRESSION VECTORS | Gene Stream Pty Ltd. (AU) | 2004-01-02 | — | — | EP | disclosed |
| US-6664066-B2 | Mutant measles virus V protein; gene expression and engineering | WYETH HOLDINGS CORPORATION | 2003-12-16 | — | — | US | disclosed |
| US-20030206925-A1 | MODIFIED MORBILLIVIRUS V PROTEINS | WYETH HOLDINGS CORPORATION | 2003-11-06 | — | — | US | disclosed |
| WO-2002083181-A1 | NOVEL COMPOSITIONS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002072844-A1 | NOVEL EXPRESSION VECTORS | GENE STREAM PTY LTD (AU) | 2002-09-19 | — | — | WO | disclosed |
| WO-2002013773-A2 | COSMETIC COMPOSITION | UNILEVER PLC (GB) | 2002-02-21 | — | — | WO | disclosed |
| CN-1232504-A | 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of order designated mononegavirales | AMERICAN CYANAMID CO (US) | 1999-10-20 | — | — | CN | disclosed |
| US-5399345-A | His at position 52 is substituted with Ser, Arg, or Glu | BOEHRINGER MANNHEIM, GMBH (DE) | 1995-03-21 | — | — | US | disclosed |
| US-5399345-A | His at position 52 is substituted with Ser, Arg, or Glu | BOEHRINGER MANNHEIM, GMBH (DE) | 1995-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148520-A1 | SINGLE-CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | IGF1R, GPR119, IRS1 | SLC7A5 454/4885PTGS1 2854/4885ALPI 4406/4885 |
| US-20120177668-A1 | IMMUNOMODULATING COMPOSITIONS COMPRISING INTERLEUKIN 13 INHIBITORS AND USES THEREFOR | IL15, ICOS, IL2 | SLC7A5 3491/4885PTGS1 428/4885ALPI 1425/4885 |
| US-11351268-B2 | FGF21 C-terminal peptide optimization | FGF23, FGFR1, FGFR3 | SLC7A5 2004/4885PTGS1 4814/4885ALPI 2210/4885 |
| US-20160024169-A1 | INSULIN-INCRETIN CONJUGATES | IAPP, GLP1R, INSR | SLC7A5 502/4885PTGS1 4599/4885ALPI 440/4885 |
| US-20190142963-A1 | FGF21 C-TERMINAL PEPTIDE OPTIMIZATION | FGF23, FGFR1, FGFR3 | SLC7A5 2004/4885PTGS1 4814/4885ALPI 2210/4885 |
| US-10696726-B2 | Insulin-incretin conjugates | GLP1R, IAPP, GIPR | SLC7A5 1933/4885PTGS1 4694/4885ALPI 306/4885 |
| US-20130203665-A1 | SINGLE-CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | IGF1R, GPR119, IRS1 | SLC7A5 454/4885PTGS1 2854/4885ALPI 4406/4885 |
| US-20180194827-A1 | INSULIN-INCRETIN CONJUGATES | GLP1R, IAPP, GIPR | SLC7A5 1933/4885PTGS1 4694/4885ALPI 306/4885 |
| US-20210198647-A1 | Enhancers of Neurolysin Activity | GAP43, NLN, BDNF | SLC7A5 1148/4885PTGS1 4683/4885ALPI 4598/4885 |
| US-20200360530-A1 | FGF21 C-TERMINAL PEPTIDE OPTIMIZATION | FGF23, FGFR1, FGFR3 | SLC7A5 2004/4885PTGS1 4814/4885ALPI 2210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.